Newsroom | 48781 results

Sorted by: Latest
Clinical Trials
-

Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA), as well as other global regulatory agencies, to conduct SAT-3247-CL-201, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept,...
-

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer...
-

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 2028. The new patent term is approximately three years longer than the previous latest-to-expire U.S. patent covering...
-

SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS

MORRISVILLE, N.C.--(BUSINESS WIRE)--SAGA Diagnostics to present data from two trials using Pathlight to evaluate neoadjuvant therapy outcomes in triple-negative breast cancer at SABCS....
-

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspect...
-

AdvanCell erhält erste Lieferung von hochaktivem Thorium-228, wodurch die einzigartige industrielle Leistungsfähigkeit und das Fachwissen des Unternehmens unterstrichen werden, die für die Skalierung der Blei-212-Produktion für gezielte...

SYDNEY & BOSTON--(BUSINESS WIRE)--  AdvanCell erhält erste Lieferung von hochaktivem Thorium-228, wodurch die einzigartige industrielle Leistungsfähigkeit und das Fachwissen des Unternehmens unterstrichen werden, die für die Skalierung der Blei-212-Produktion für gezielte Alpha-Therapien erforderlich sind AdvanCell, ein im klinischen Stadium tätiges Radiopharmazieunternehmen, das innovative zielgerichtete Alpha-Therapien für Krebs entwickelt, gab heute den Erhalt der ersten Lieferung von hochak...
-

AdvanCell reçoit sa première livraison de thorium-228 à forte activité, mettant ainsi en évidence une capacité et une expertise uniques dans l'industrie, essentielles pour augmenter la production de plomb-212 destiné aux traitements alpha ciblés

SYDNEY et BOSTON--(BUSINESS WIRE)--AdvanCell, une société radiopharmaceutique en phase clinique développant des traitements alpha ciblés innovants contre le cancer, a annoncé aujourd'hui avoir reçu la première livraison de 228Th à forte activité, l'isotope parent du 212Pb et matière première essentielle pour produire l'émetteur alpha 212Pb, utilisé pour fabriquer l'ADVC001, principal actif de la société, et d'autres radiothérapies à base de 212Pb en développement. Cette livraison représente une...
-

Samenvatting: AdvanCell ontvangt eerste levering van hoogactief thorium-228, een bewijs van de unieke industriële capaciteit en expertise die essentieel zijn voor het opschalen van de productie van lood-212 voor gerichte alfatherapieën

SYDNEY & BOSTON--(BUSINESS WIRE)--AdvanCell, een radiofarmaceutisch bedrijf in de klinische fase dat innovatieve gerichte alfatherapieën voor kanker ontwikkelt, heeft vandaag aangekondigd dat het de eerste levering van hoogactief thorium-228 heeft ontvangen. 228Th, de moederisotoop van 212Pb en een belangrijk uitgangsmateriaal voor de productie van de alfastraler 212Pb, wordt gebruikt voor de productie van ADVC001, de belangrijkste asset van het bedrijf, en andere op 212Pb gebaseerde radioligan...
-

Resumen: AdvanCell recibe la primera entrega de Torio-228 de alta actividad, lo que hace posible una capacidad y unos conocimientos de la industria únicos y esenciales para aumentar la producción de Plomo-212 para terapias alfa dirigidas

SÍDNEY y BOSTON--(BUSINESS WIRE)--AdvanCell, una empresa radiofarmacéutica de fase clínica que desarrolla terapias alfa dirigidas innovadoras para el cáncer, anunció hoy que ha recibido la primera entrega de 228Th de alta actividad, el isótopo padre de 212Pb y un material de partida clave para producir el 212Pb emisor alfa, que se utiliza para fabricar ADVC001, el principal activo de la empresa, y otras terapias con radioligandos basadas en 212Pb en la línea de productos. El comunicado en el id...
-

Riassunto: AdvanCell riceve la prima fornitura di torio-228 ad attività elevata, evidenziando capacità e competenze industriali uniche, fondamentali per scalare la produzione di piombo-212 per terapie alfa mirate

SYDNEY e BOSTON--(BUSINESS WIRE)--AdvanCell, azienda radiofarmaceutica in fase clinica specializzata in terapie oncologiche alfa mirate, ha annunciato oggi di aver ricevuto la prima consegna di 228Th ad attività elevata, l'isotopo originario di 212Pb e un materiale di partenza essenziale nella produzione di 212Pb, un emettitore alfa, utilizzato nella fabbricazione di ADVC001, il prodotto di punta dell'azienda, e altre terapie con radioligandi a base di 212Pb in programma. Il testo originale del...